# GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery

> **NCT00878163** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 55 (actual)

## Conditions studied

- Adult Solid Neoplasm
- Pancreatic Acinar Cell Carcinoma
- Pancreatic Ductal Adenocarcinoma
- Recurrent Pancreatic Carcinoma
- Stage IV Pancreatic Cancer AJCC v6 and v7

## Interventions

- **OTHER:** Diagnostic Laboratory Biomarker Analysis
- **DRUG:** Erlotinib Hydrochloride
- **DRUG:** Gemcitabine Hydrochloride
- **DRUG:** Vismodegib

## Key facts

- **NCT ID:** NCT00878163
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2009-03-31
- **Primary completion:** 2013-01-22
- **Final completion:** 2027-03-06
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00878163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00878163, "GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00878163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*